EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring the Therapeutic Potential of 177Lu-PSMA-617 in a Mouse Model of Prostate Cancer Bone Metastases

Cheng-Liang Peng iD, Chun-Tang Chen, I-Chung Tang

International Journal of Molecular Sciences · 21.06.2025 · 26 (13) · 5970

DOI: 10.3390/ijms26135970 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.06.2025. Verfasst von Cheng-Liang Peng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Isotope Application Research, National Atomic Research Institute, Taoyuan 325207, Taiwan. Hauptthemen laut MEDLINE: Bone Neoplasms, Heterocyclic Compounds, 1-Ring, Dipeptides, Lutetium. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer is the second leading cause of cancer-related death in men, with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases representing a critical clinical challenge. Although radium-223 (Ra-223) is approved for treating mCRPC with bone metastases, its efficacy remains limited, necessitating the development of more effective therapies. This study investigates the therapeutic potential of 177Lu-PSMA-617, a PSMA-targeted radiopharmaceutical, in a murine model of prostate cancer bone metastases. To our knowledge, this is the first study to systematically evaluate 177Lu-PSMA-617 in an orthotopic bone metastatic prostate cancer model, providing a clinically relevant preclinical platform to assess both imaging and therapeutic performance. We conducted comprehensive preclinical evaluations, including synthesis, stability analysis, cell binding assays, nuclear imaging, in vivo biodistribution, pharmacokinetics, and antitumor efficacy. The synthesis of 177Lu-PSMA-617 demonstrated high radiochemical yield (99.2%), molar activity (25.5 GBq/μmol), and purity (>98%), indicating high product quality. Stability studies confirmed minimal release of free Lutetium-177, maintaining the compound’s integrity under physiological conditions. In vitro assays showed selective binding and internalization in PSMA-positive LNCaP prostate cancer cells, with negligible uptake in PSMA-negative PC-3 cells. In vivo biodistribution studies demonstrated efficient tumor targeting, with peak uptake in LNCaP tumors (23.31 ± 0.94 %IA/g) at 4 h post-injection. The radiopharmaceutical exhibited favorable pharmacokinetics, with high tumor-to-background ratios (tumor-to-blood, 434.4; tumor-to-muscle, 857.4). Therapeutic efficacy was confirmed by significant survival extension in treated mice (30.7% for 37 MBq and 53.8% for 111 MBq), with median survival times of 34 and 40 days, respectively, compared to 26 days in the control group. Radiation dosimetry analysis indicated a favorable safety profile with a calculated effective dose of 0.127 mSv/MBq. These findings highlight the novelty and translational relevance of using 177Lu-PSMA-617 in a clinically relevant bone metastasis model, reinforcing its potential as a dual-purpose agent for both targeted therapy and molecular imaging in advanced prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsHeterocyclic Compounds, 1-RingDipeptidesLutetiumRadioisotopesProstatic NeoplasmsRadiopharmaceuticalsAnimalsMaleMiceHumansCell Line, TumorDisease Models, AnimalTissue DistributionXenograft Model Antitumor AssaysProstatic Neoplasms, Castration-ResistantProstate-Specific Antigen

Stichwörter der Autor:innen

177Lu-PSMA-617bone metastasispreclinical modelprostate cancertargeted radionuclide therapy

Substanzen

Heterocyclic Compounds, 1-RingDipeptidesLutetiumRadioisotopesRadiopharmaceuticalsPSMA-617Lutetium-177Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Isotope Application Research, National Atomic Research Institute, Taoyuan 325207, Taiwan.

ORCID-Profile: Cheng-Liang Peng

Zitieren

APA

Peng, C. L., Chen, C. T., & Tang, I. C. (2025). Exploring the Therapeutic Potential of 177Lu-PSMA-617 in a Mouse Model of Prostate Cancer Bone Metastases. International Journal of Molecular Sciences, 26(13), 5970. https://doi.org/10.3390/ijms26135970

Vancouver

Peng CL, Chen CT, Tang IC. Exploring the Therapeutic Potential of 177Lu-PSMA-617 in a Mouse Model of Prostate Cancer Bone Metastases. International Journal of Molecular Sciences. 2025;26(13):5970. doi:10.3390/ijms26135970

BibTeX
@article{Peng2025,
  author = {Peng, Cheng-Liang and Chen, Chun-Tang and Tang, I-Chung},
  title = {Exploring the Therapeutic Potential of 177Lu-PSMA-617 in a Mouse Model of Prostate Cancer Bone Metastases},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {13},
  pages = {5970},
  doi = {10.3390/ijms26135970}
}
Kostenlos starten →